PDF(1793 KB)
Cost-effectiveness analysis of durvalumab versus atezolizumab as a first-line treatment for extensive-stage small cell lung cancer
CHEN Yeli, LONG Yunchun, CHEN Fang, CHEN Yu
Chinese Journal of Hospital Pharmacy ›› 2024, Vol. 44 ›› Issue (7) : 815-821.
PDF(1793 KB)
PDF(1793 KB)
Cost-effectiveness analysis of durvalumab versus atezolizumab as a first-line treatment for extensive-stage small cell lung cancer
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
